Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750806 | 0.87 | MAOA (0.50) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL5026521 | 0.85 | CYP19A1 (0.47) | MAOAKDM4EALDH1A1CDC25BPDE4B | |
| SCHEMBL5026641 | 0.85 | CYP19A1 (0.47) | KDM4EALDH1A1LMNACYP19A1CYP11B1 | |
| SCHEMBL5018032 | 0.82 | PDE4B (0.46) | MAOANPC1KDM4EALDH1A1RAB9A | |
| SCHEMBL1301906 | 0.82 | MAOA (0.47) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL5022276 | 0.81 | EDNRA (0.49) | KDM4EALDH1A1CA9CYP2C9EDNRA | |
| SCHEMBL5025338 | 0.81 | MCL1 (0.47) | NPC1KDM4EALDH1A1LMNARAB9A | |
| SCHEMBL5026498 | 0.81 | CA12 (0.40) | NPC1KDM4EALDH1A1RAB9ACDC25B | |
| SCHEMBL5548694 | 0.81 | CA12 (0.44) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL5548004 | 0.81 | ALDH1A1 (0.55) | NPC1KDM4EALDH1A1RAB9ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225205-B1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2013-01-02 | — | — | EP | disclosed |
| US-7968724-B2 | Ester derivatives as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| EP-2225205-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009077068-A9 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2009-08-20 | — | — | WO | disclosed |
| US-20090170903-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-07-02 | — | — | US | disclosed |
| WO-2009077068-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070913-A1 | Ester derivatives as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-06-17 | — | — | EP | disclosed |
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | disclosed |
| EP-1554262-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Glenmark Pharmaceuticals Limited (IN) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037805-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | MAOA 977/4885NPC1 853/4885KDM4E 4205/4885 |
| US-20090170903-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE5A | MAOA 301/4885NPC1 2240/4885KDM4E 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.